Photo from Giulia Bertelli on Unsplash Seed financingTECregen raises €11m seed round to advance thymus regenerationSwiss biotechnology company TECregen, based in Basel, has raised CHF 10 million (about €11 million) in seed financing to advance therapies designed to restore immune function by regenerating the thymus, … more ➔
EngitixFundraisingBillionaire Mike Platt backs Engitix for the second time with a $25 million series A extension4 years after its initial series A round, Engitix has completed a $25 million series A extension, led by Netherton Investments, which invests on behalf of billionaire hedge fund founder Mike Platt. The … more ➔
Evotec SEAcquisitionEvotec benefits from Dark Blue acquisition by AmgenThe acquisition of Oxford-based Dark Blue Therapeutics by US biotechnology company Amgen Inc. has produced a German beneficiary: Hamburg-based Evotec SE. Through an early collaboration with the Oxford … more ➔
CollaborationBasilea strikes up to $48.5m antifungal deal with U.S. biotech ProkaryoticsSwiss anti-infectives specialist Basilea Pharmaceutica has entered a research collaboration with U.S.-based Prokaryotics to develop a novel broad-spectrum antifungal aimed at treating severe invasive … more ➔
Clinical trialPolish biotech JPP Biologics reports positive Phase I data for first-in-class biologic for immune diseasesJJP Biologics has announced positive top-line results from a Phase I clinical trial of JJP-1212, its first-in-class anti-CD89 antagonist being developed for IgA-mediated inflammatory diseases. The data … more ➔
Genentech Corp. / RocheCollaborationAmgen selects German Disco Pharma to collaborate in multi-million-dollar dealThe new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled … more ➔
M&AAmgen acquires Dark Blue Therapeutics for up to $840 millionAmgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown … more ➔
Photo from Shawn Day on Unsplash Drug developmentLoQus23 moves Huntington’s disease candidate into developmentUK-based biotech LoQus23 Therapeutics is advancing an oral small molecule targeting a fundamental genetic process in Huntington’s disease, a rare neurodegenerative disorder. more ➔
ManagementWith Vyvgart established, argenx looks beyond its founder CEOThe Dutch biotech argenx has announced a planned leadership transition to be effective in May after its annual shareholder meeting. Tim Van Hauwermeiren, co-founder and long-time Chief Executive Officer, … more ➔
R&D collaborationsServier and Insilico sign an $888 million AI oncology discovery dealOn January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for … more ➔
Photo from Giulia Bertelli on Unsplash 
Engitix
Evotec SE
Genentech Corp. / Roche
Photo from Shawn Day on Unsplash 
